MiniMed targets about 10.5% fiscal 2027 organic revenue growth as Flex scales and Fit eyes U.S. launch by summer 2027
AI Market Summary
MiniMed reported strong organic growth and raised FY2027 revenue-growth guidance, supported by Flex expansion (including CE mark) and a U.S. regulatory pathway for Fit via a submitted 510(k), with a targeted summer 2027 launch. The update is constructive for the company but is idiosyncratic and not broadly market-moving for major crypto assets; near-term impact should be limited outside relevant healthcare equities.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-1.98%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
On its fiscal 2027 first-quarter earnings call, MiniMed reported 16% organic growth. The company said the Flex product continues to expand and has received a CE mark, while Fit has filed a 510(k) application and is expected to launch in the U.S. by summer 2027. MiniMed raised its outlook and now projects about 10.5% organic revenue growth for fiscal 2027.
